Milestone Pharmaceuticals (NASDAQ:MIST) executives highlighted the company’s transition to commercialization during a ...

The curtain has officially come down on Bob Iger’s second run as CEO of Disney — marking the end of a years-long succession ...

Silvaco Group surged over 50% post-Q4 FY25 earnings last week, driven by strong TCAD bookings and explosive SIP revenue ...

An inability to satisfy ratio or incurrence-based tests in leveraged finance loan agreements can lead to a borrower group ...

For one, Cathie Wood can't get enough of CRSP stock, recently picking up another 438,000 shares across the ARK Innovation ETF ...

But as the FT has reported closely, the golden age has morphed into a more uncertain moment as funds face falling returns, ...

Politically, the conversation ranges from questions of rights and entitlements to debates over zoning, transportation, and ...

Greetings, everyone, and welcome to Star Equity Holdings Fourth Quarter 2025 Financial Results Conference Call. Please be advised that the discussions on today's call may include forward-looking ...

Total revenue of $41.8 million in Q4 2025, up 86% as reported and 23% on an adjusted pro forma basis versus Q4 2024Greenbrook clinic revenue of ...

Detailed price information for Collegium Pharma (COLL-Q) from The Globe and Mail including charting and trades.

Did the lawyers who drafted the U.S. opinion even read Israel’s arguments?

The latest PV Reliability Workshop highlighted why investing in PV reliability and quality is more important than ever.